Citi Maintains Buy on Hologic (HOLX)

Citi is out with its report today on Hologic HOLX, maintaining Buy.

In a note to clients, Citi writes, "Hologic recently presented at our annual healthcare conference in NYC and reviewed its strategic plan and gave further detail on initial customer interest for tomosynthesis – recall the product was approved on 2/11/11. The company also fielded investor questions on its outstanding convertible debt and the Cervista HPV opportunity. We maintain our Buy rating and $24 target price. The main focus for the stock remains the tomosynthesis launch."

Shares of HOLX closed Friday at $21.08, down 0.28% from Thursday's close.